Global Adult Vaccines- Market

Adult Vaccines- Comprehensive Study by Type (Influenza, Tetanus/Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis, Others), End Users (Medical Care, Healthy, Hospital), Technology (Live Attenuated Vaccines, Inactivated Viral or Bacterial Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines), Indication (Pneumococcal Disease (Influenza, Human Papilloma Virus), Meningococcal Disease (Rotavirus, Varicella), Diphtheria, Pertussis, & Tetanus {DTP}, Polio, Hepatitis, Measles, Mumps, Rubella {MMR}, Others) Players and Region - Global Market Outlook to 2026

Adult Vaccines- Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Adult Vaccines-?
Adult vaccines are taken with the purpose to cure seasonal flu and infectious diseases. Globally, cases of virus borne contagious diseases have been reported which require great concern. The development of adult vaccines are aimed to cure diseases of particular kind with each vaccines having different purpose. These vaccines are designed for different set of people which include healthcare workers, pregnant workers, international worker as well as for immigrants or refugees.

The market study is broken down by Type (Influenza, Tetanus/Diphtheria/Pertussis, Varicella, Human Papillomavirus, Zoster, Measles/mumps/Rubella, Pneumococcal, Hepatitis and Others) and major geographies with country level break-up. and may see market size of USD22.5 Billion by 2026.

Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Adult Vaccines- market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline (United Kingdom), Sanofi Pasteur (France), Merck (United States), Novartis (Switzerland), Pfizer (United States), BioCSL (Seqirus) (United Kingdom) and Johnson & Johnson (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Protein Sciences (United States), Serum Institute of India (India), MedImmune (United States) and AstraZeneca (United Kingdom).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Adult Vaccines- market by Type, Application and Region.

On the basis of geography, the market of Adult Vaccines- has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Medical Care will boost the Adult Vaccines- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Live Attenuated Vaccines will boost the Adult Vaccines- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indication, the sub-segment i.e. Pneumococcal Disease (Influenza, Human Papilloma Virus) will boost the Adult Vaccines- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.


The U.S. Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and ResearchExternal (CBER) is responsible for regulating vaccines in the United States. The sponsor of a new vaccine product follows a multi-step approval process which are "An Investigational New Drug application, Pre-licensure vaccine clinical trials, A Biologics License Application (BLA), Inspection of the manufacturing facility, Presentation of findings to FDA’s Vaccines and Related Biological Products Advisory CommitteeExternal (VRBPAC) and Usability testing of product labeling.

Market Trend
  • Emergence of Protein-Conjugate Vaccines for Adults
  • Launch of Customized vaccines at Lower Cost

Market Drivers
  • Growing Focus on Preventing Diseases Leading to Rise in Demand
  • Rising Government Expenditure to Increase Vaccines Awareness

Opportunities
  • Rising Demand from Emerging Countries
  • World Health Organization (WHO) Favorable Initiatives

Restraints
  • High Manufacturing Cost Involved in Adult Vaccines
  • Stringent Regulatory Guidelines

Challenges
  • Adverse Effect of Vaccine If Taken Without Prescription
  • High Cost Involved in Research and Development of Adult Vaccines


Key Target Audience
Adult Vaccines Manufacturers, Distributors/Suppliers, Market and Research Firms, Potential Investors, Government Agencies, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Influenza
  • Tetanus/Diphtheria/Pertussis
  • Varicella, Human Papillomavirus
  • Zoster
  • Measles/mumps/Rubella
  • Pneumococcal
  • Hepatitis
  • Others
By End Users
  • Medical Care
  • Healthy
  • Hospital

By Technology
  • Live Attenuated Vaccines
  • Inactivated Viral or Bacterial Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines

By Indication
  • Pneumococcal Disease (Influenza, Human Papilloma Virus)
  • Meningococcal Disease (Rotavirus, Varicella)
  • Diphtheria, Pertussis, & Tetanus {DTP}
  • Polio
  • Hepatitis
  • Measles
  • Mumps
  • Rubella {MMR}
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Focus on Preventing Diseases Leading to Rise in Demand
      • 3.2.2. Rising Government Expenditure to Increase Vaccines Awareness
    • 3.3. Market Challenges
      • 3.3.1. Adverse Effect of Vaccine If Taken Without Prescription
      • 3.3.2. High Cost Involved in Research and Development of Adult Vaccines
    • 3.4. Market Trends
      • 3.4.1. Emergence of Protein-Conjugate Vaccines for Adults
      • 3.4.2. Launch of Customized vaccines at Lower Cost
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Adult Vaccines-, by Type, End Users, Technology, Indication and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Adult Vaccines- (Value)
      • 5.2.1. Global Adult Vaccines- by: Type (Value)
        • 5.2.1.1. Influenza
        • 5.2.1.2. Tetanus/Diphtheria/Pertussis
        • 5.2.1.3. Varicella, Human Papillomavirus
        • 5.2.1.4. Zoster
        • 5.2.1.5. Measles/mumps/Rubella
        • 5.2.1.6. Pneumococcal
        • 5.2.1.7. Hepatitis
        • 5.2.1.8. Others
      • 5.2.2. Global Adult Vaccines- by: End Users (Value)
        • 5.2.2.1. Medical Care
        • 5.2.2.2. Healthy
        • 5.2.2.3. Hospital
      • 5.2.3. Global Adult Vaccines- by: Technology (Value)
        • 5.2.3.1. Live Attenuated Vaccines
        • 5.2.3.2. Inactivated Viral or Bacterial Vaccines
        • 5.2.3.3. Toxoid Vaccines
        • 5.2.3.4. Recombinant Vaccines
        • 5.2.3.5. Conjugate Vaccines
      • 5.2.4. Global Adult Vaccines- by: Indication (Value)
        • 5.2.4.1. Pneumococcal Disease (Influenza, Human Papilloma Virus)
        • 5.2.4.2. Meningococcal Disease (Rotavirus, Varicella)
        • 5.2.4.3. Diphtheria, Pertussis, & Tetanus {DTP}
        • 5.2.4.4. Polio
        • 5.2.4.5. Hepatitis
        • 5.2.4.6. Measles
        • 5.2.4.7. Mumps
        • 5.2.4.8. Rubella {MMR}
        • 5.2.4.9. Others
      • 5.2.5. Global Adult Vaccines- Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Adult Vaccines- (Price)
      • 5.3.1. Global Adult Vaccines- by: Type (Price)
  • 6. Adult Vaccines-: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi Pasteur (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BioCSL (Seqirus) (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Adult Vaccines- Sale, by Type, End Users, Technology, Indication and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Adult Vaccines- (Value)
      • 7.2.1. Global Adult Vaccines- by: Type (Value)
        • 7.2.1.1. Influenza
        • 7.2.1.2. Tetanus/Diphtheria/Pertussis
        • 7.2.1.3. Varicella, Human Papillomavirus
        • 7.2.1.4. Zoster
        • 7.2.1.5. Measles/mumps/Rubella
        • 7.2.1.6. Pneumococcal
        • 7.2.1.7. Hepatitis
        • 7.2.1.8. Others
      • 7.2.2. Global Adult Vaccines- by: End Users (Value)
        • 7.2.2.1. Medical Care
        • 7.2.2.2. Healthy
        • 7.2.2.3. Hospital
      • 7.2.3. Global Adult Vaccines- by: Technology (Value)
        • 7.2.3.1. Live Attenuated Vaccines
        • 7.2.3.2. Inactivated Viral or Bacterial Vaccines
        • 7.2.3.3. Toxoid Vaccines
        • 7.2.3.4. Recombinant Vaccines
        • 7.2.3.5. Conjugate Vaccines
      • 7.2.4. Global Adult Vaccines- by: Indication (Value)
        • 7.2.4.1. Pneumococcal Disease (Influenza, Human Papilloma Virus)
        • 7.2.4.2. Meningococcal Disease (Rotavirus, Varicella)
        • 7.2.4.3. Diphtheria, Pertussis, & Tetanus {DTP}
        • 7.2.4.4. Polio
        • 7.2.4.5. Hepatitis
        • 7.2.4.6. Measles
        • 7.2.4.7. Mumps
        • 7.2.4.8. Rubella {MMR}
        • 7.2.4.9. Others
      • 7.2.5. Global Adult Vaccines- Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Adult Vaccines- (Price)
      • 7.3.1. Global Adult Vaccines- by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Adult Vaccines-: by Type(USD Billion)
  • Table 2. Adult Vaccines- Influenza , by Region USD Billion (2015-2020)
  • Table 3. Adult Vaccines- Tetanus/Diphtheria/Pertussis , by Region USD Billion (2015-2020)
  • Table 4. Adult Vaccines- Varicella, Human Papillomavirus , by Region USD Billion (2015-2020)
  • Table 5. Adult Vaccines- Zoster , by Region USD Billion (2015-2020)
  • Table 6. Adult Vaccines- Measles/mumps/Rubella , by Region USD Billion (2015-2020)
  • Table 7. Adult Vaccines- Pneumococcal , by Region USD Billion (2015-2020)
  • Table 8. Adult Vaccines- Hepatitis , by Region USD Billion (2015-2020)
  • Table 9. Adult Vaccines- Others , by Region USD Billion (2015-2020)
  • Table 10. Adult Vaccines-: by End Users(USD Billion)
  • Table 11. Adult Vaccines- Medical Care , by Region USD Billion (2015-2020)
  • Table 12. Adult Vaccines- Healthy , by Region USD Billion (2015-2020)
  • Table 13. Adult Vaccines- Hospital , by Region USD Billion (2015-2020)
  • Table 14. Adult Vaccines-: by Technology(USD Billion)
  • Table 15. Adult Vaccines- Live Attenuated Vaccines , by Region USD Billion (2015-2020)
  • Table 16. Adult Vaccines- Inactivated Viral or Bacterial Vaccines , by Region USD Billion (2015-2020)
  • Table 17. Adult Vaccines- Toxoid Vaccines , by Region USD Billion (2015-2020)
  • Table 18. Adult Vaccines- Recombinant Vaccines , by Region USD Billion (2015-2020)
  • Table 19. Adult Vaccines- Conjugate Vaccines , by Region USD Billion (2015-2020)
  • Table 20. Adult Vaccines-: by Indication(USD Billion)
  • Table 21. Adult Vaccines- Pneumococcal Disease (Influenza, Human Papilloma Virus) , by Region USD Billion (2015-2020)
  • Table 22. Adult Vaccines- Meningococcal Disease (Rotavirus, Varicella) , by Region USD Billion (2015-2020)
  • Table 23. Adult Vaccines- Diphtheria, Pertussis, & Tetanus {DTP} , by Region USD Billion (2015-2020)
  • Table 24. Adult Vaccines- Polio , by Region USD Billion (2015-2020)
  • Table 25. Adult Vaccines- Hepatitis , by Region USD Billion (2015-2020)
  • Table 26. Adult Vaccines- Measles , by Region USD Billion (2015-2020)
  • Table 27. Adult Vaccines- Mumps , by Region USD Billion (2015-2020)
  • Table 28. Adult Vaccines- Rubella {MMR} , by Region USD Billion (2015-2020)
  • Table 29. Adult Vaccines- Others , by Region USD Billion (2015-2020)
  • Table 30. South America Adult Vaccines-, by Country USD Billion (2015-2020)
  • Table 31. South America Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 32. South America Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 33. South America Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 34. South America Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 35. Brazil Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 36. Brazil Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 37. Brazil Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 38. Brazil Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 39. Argentina Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 40. Argentina Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 41. Argentina Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 42. Argentina Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 43. Rest of South America Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 44. Rest of South America Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 45. Rest of South America Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 46. Rest of South America Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 47. Asia Pacific Adult Vaccines-, by Country USD Billion (2015-2020)
  • Table 48. Asia Pacific Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 49. Asia Pacific Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 50. Asia Pacific Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 51. Asia Pacific Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 52. China Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 53. China Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 54. China Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 55. China Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 56. Japan Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 57. Japan Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 58. Japan Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 59. Japan Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 60. India Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 61. India Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 62. India Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 63. India Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 64. South Korea Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 65. South Korea Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 66. South Korea Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 67. South Korea Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 68. Taiwan Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 69. Taiwan Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 70. Taiwan Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 71. Taiwan Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 72. Australia Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 73. Australia Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 74. Australia Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 75. Australia Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 76. Rest of Asia-Pacific Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 77. Rest of Asia-Pacific Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 78. Rest of Asia-Pacific Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 79. Rest of Asia-Pacific Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 80. Europe Adult Vaccines-, by Country USD Billion (2015-2020)
  • Table 81. Europe Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 82. Europe Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 83. Europe Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 84. Europe Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 85. Germany Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 86. Germany Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 87. Germany Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 88. Germany Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 89. France Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 90. France Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 91. France Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 92. France Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 93. Italy Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 94. Italy Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 95. Italy Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 96. Italy Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 97. United Kingdom Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 98. United Kingdom Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 99. United Kingdom Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 100. United Kingdom Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 101. Netherlands Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 102. Netherlands Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 103. Netherlands Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 104. Netherlands Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 105. Rest of Europe Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 106. Rest of Europe Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 107. Rest of Europe Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 108. Rest of Europe Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 109. MEA Adult Vaccines-, by Country USD Billion (2015-2020)
  • Table 110. MEA Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 111. MEA Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 112. MEA Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 113. MEA Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 114. Middle East Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 115. Middle East Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 116. Middle East Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 117. Middle East Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 118. Africa Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 119. Africa Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 120. Africa Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 121. Africa Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 122. North America Adult Vaccines-, by Country USD Billion (2015-2020)
  • Table 123. North America Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 124. North America Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 125. North America Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 126. North America Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 127. United States Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 128. United States Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 129. United States Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 130. United States Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 131. Canada Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 132. Canada Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 133. Canada Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 134. Canada Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 135. Mexico Adult Vaccines-, by Type USD Billion (2015-2020)
  • Table 136. Mexico Adult Vaccines-, by End Users USD Billion (2015-2020)
  • Table 137. Mexico Adult Vaccines-, by Technology USD Billion (2015-2020)
  • Table 138. Mexico Adult Vaccines-, by Indication USD Billion (2015-2020)
  • Table 139. Adult Vaccines-: by Type(USD/Units)
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Adult Vaccines-: by Type(USD Billion)
  • Table 148. Adult Vaccines- Influenza , by Region USD Billion (2021-2026)
  • Table 149. Adult Vaccines- Tetanus/Diphtheria/Pertussis , by Region USD Billion (2021-2026)
  • Table 150. Adult Vaccines- Varicella, Human Papillomavirus , by Region USD Billion (2021-2026)
  • Table 151. Adult Vaccines- Zoster , by Region USD Billion (2021-2026)
  • Table 152. Adult Vaccines- Measles/mumps/Rubella , by Region USD Billion (2021-2026)
  • Table 153. Adult Vaccines- Pneumococcal , by Region USD Billion (2021-2026)
  • Table 154. Adult Vaccines- Hepatitis , by Region USD Billion (2021-2026)
  • Table 155. Adult Vaccines- Others , by Region USD Billion (2021-2026)
  • Table 156. Adult Vaccines-: by End Users(USD Billion)
  • Table 157. Adult Vaccines- Medical Care , by Region USD Billion (2021-2026)
  • Table 158. Adult Vaccines- Healthy , by Region USD Billion (2021-2026)
  • Table 159. Adult Vaccines- Hospital , by Region USD Billion (2021-2026)
  • Table 160. Adult Vaccines-: by Technology(USD Billion)
  • Table 161. Adult Vaccines- Live Attenuated Vaccines , by Region USD Billion (2021-2026)
  • Table 162. Adult Vaccines- Inactivated Viral or Bacterial Vaccines , by Region USD Billion (2021-2026)
  • Table 163. Adult Vaccines- Toxoid Vaccines , by Region USD Billion (2021-2026)
  • Table 164. Adult Vaccines- Recombinant Vaccines , by Region USD Billion (2021-2026)
  • Table 165. Adult Vaccines- Conjugate Vaccines , by Region USD Billion (2021-2026)
  • Table 166. Adult Vaccines-: by Indication(USD Billion)
  • Table 167. Adult Vaccines- Pneumococcal Disease (Influenza, Human Papilloma Virus) , by Region USD Billion (2021-2026)
  • Table 168. Adult Vaccines- Meningococcal Disease (Rotavirus, Varicella) , by Region USD Billion (2021-2026)
  • Table 169. Adult Vaccines- Diphtheria, Pertussis, & Tetanus {DTP} , by Region USD Billion (2021-2026)
  • Table 170. Adult Vaccines- Polio , by Region USD Billion (2021-2026)
  • Table 171. Adult Vaccines- Hepatitis , by Region USD Billion (2021-2026)
  • Table 172. Adult Vaccines- Measles , by Region USD Billion (2021-2026)
  • Table 173. Adult Vaccines- Mumps , by Region USD Billion (2021-2026)
  • Table 174. Adult Vaccines- Rubella {MMR} , by Region USD Billion (2021-2026)
  • Table 175. Adult Vaccines- Others , by Region USD Billion (2021-2026)
  • Table 176. South America Adult Vaccines-, by Country USD Billion (2021-2026)
  • Table 177. South America Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 178. South America Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 179. South America Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 180. South America Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 181. Brazil Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 182. Brazil Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 183. Brazil Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 184. Brazil Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 185. Argentina Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 186. Argentina Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 187. Argentina Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 188. Argentina Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 189. Rest of South America Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 190. Rest of South America Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 191. Rest of South America Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 192. Rest of South America Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 193. Asia Pacific Adult Vaccines-, by Country USD Billion (2021-2026)
  • Table 194. Asia Pacific Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 195. Asia Pacific Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 196. Asia Pacific Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 197. Asia Pacific Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 198. China Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 199. China Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 200. China Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 201. China Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 202. Japan Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 203. Japan Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 204. Japan Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 205. Japan Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 206. India Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 207. India Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 208. India Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 209. India Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 210. South Korea Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 211. South Korea Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 212. South Korea Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 213. South Korea Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 214. Taiwan Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 215. Taiwan Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 216. Taiwan Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 217. Taiwan Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 218. Australia Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 219. Australia Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 220. Australia Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 221. Australia Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 222. Rest of Asia-Pacific Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 223. Rest of Asia-Pacific Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 224. Rest of Asia-Pacific Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 225. Rest of Asia-Pacific Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 226. Europe Adult Vaccines-, by Country USD Billion (2021-2026)
  • Table 227. Europe Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 228. Europe Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 229. Europe Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 230. Europe Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 231. Germany Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 232. Germany Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 233. Germany Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 234. Germany Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 235. France Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 236. France Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 237. France Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 238. France Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 239. Italy Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 240. Italy Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 241. Italy Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 242. Italy Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 243. United Kingdom Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 244. United Kingdom Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 245. United Kingdom Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 246. United Kingdom Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 247. Netherlands Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 248. Netherlands Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 249. Netherlands Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 250. Netherlands Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 251. Rest of Europe Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 252. Rest of Europe Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 253. Rest of Europe Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 254. Rest of Europe Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 255. MEA Adult Vaccines-, by Country USD Billion (2021-2026)
  • Table 256. MEA Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 257. MEA Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 258. MEA Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 259. MEA Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 260. Middle East Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 261. Middle East Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 262. Middle East Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 263. Middle East Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 264. Africa Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 265. Africa Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 266. Africa Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 267. Africa Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 268. North America Adult Vaccines-, by Country USD Billion (2021-2026)
  • Table 269. North America Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 270. North America Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 271. North America Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 272. North America Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 273. United States Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 274. United States Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 275. United States Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 276. United States Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 277. Canada Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 278. Canada Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 279. Canada Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 280. Canada Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 281. Mexico Adult Vaccines-, by Type USD Billion (2021-2026)
  • Table 282. Mexico Adult Vaccines-, by End Users USD Billion (2021-2026)
  • Table 283. Mexico Adult Vaccines-, by Technology USD Billion (2021-2026)
  • Table 284. Mexico Adult Vaccines-, by Indication USD Billion (2021-2026)
  • Table 285. Adult Vaccines-: by Type(USD/Units)
  • Table 286. Research Programs/Design for This Report
  • Table 287. Key Data Information from Secondary Sources
  • Table 288. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Adult Vaccines-: by Type USD Billion (2015-2020)
  • Figure 5. Global Adult Vaccines-: by End Users USD Billion (2015-2020)
  • Figure 6. Global Adult Vaccines-: by Technology USD Billion (2015-2020)
  • Figure 7. Global Adult Vaccines-: by Indication USD Billion (2015-2020)
  • Figure 8. South America Adult Vaccines- Share (%), by Country
  • Figure 9. Asia Pacific Adult Vaccines- Share (%), by Country
  • Figure 10. Europe Adult Vaccines- Share (%), by Country
  • Figure 11. MEA Adult Vaccines- Share (%), by Country
  • Figure 12. North America Adult Vaccines- Share (%), by Country
  • Figure 13. Global Adult Vaccines-: by Type USD/Units (2015-2020)
  • Figure 14. Global Adult Vaccines- share by Players 2020 (%)
  • Figure 15. Global Adult Vaccines- share by Players (Top 3) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi Pasteur (France) Revenue: by Geography 2020
  • Figure 21. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck (United States) Revenue: by Geography 2020
  • Figure 23. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 25. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer (United States) Revenue: by Geography 2020
  • Figure 27. BioCSL (Seqirus) (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. BioCSL (Seqirus) (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 31. Global Adult Vaccines-: by Type USD Billion (2021-2026)
  • Figure 32. Global Adult Vaccines-: by End Users USD Billion (2021-2026)
  • Figure 33. Global Adult Vaccines-: by Technology USD Billion (2021-2026)
  • Figure 34. Global Adult Vaccines-: by Indication USD Billion (2021-2026)
  • Figure 35. South America Adult Vaccines- Share (%), by Country
  • Figure 36. Asia Pacific Adult Vaccines- Share (%), by Country
  • Figure 37. Europe Adult Vaccines- Share (%), by Country
  • Figure 38. MEA Adult Vaccines- Share (%), by Country
  • Figure 39. North America Adult Vaccines- Share (%), by Country
  • Figure 40. Global Adult Vaccines-: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (United Kingdom)
  • Sanofi Pasteur (France)
  • Merck (United States)
  • Novartis (Switzerland)
  • Pfizer (United States)
  • BioCSL (Seqirus) (United Kingdom)
  • Johnson & Johnson (United States)
Additional players considered in the study are as follows:
Protein Sciences (United States) , Serum Institute of India (India) , MedImmune (United States) , AstraZeneca (United Kingdom)
Select User Access Type

Key Highlights of Report


Oct 2021 207 Pages 97 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Adult Vaccines- Market Quantitative research analysis
Global Adult Vaccines- Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline (United Kingdom), Sanofi Pasteur (France), Merck (United States), Novartis (Switzerland), Pfizer (United States), BioCSL (Seqirus) (United Kingdom) and Johnson & Johnson (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates Adult Vaccines- Market to reach USD22.5 Billion by 2026.

Know More About Global Adult Vaccines- Market Report?

Have a Query? Click Here

Other Related Reports

Cardiac Stimulator Comprehensive Study by Type (Implantable Cardiac Stimulator, External Cardiac Stimulator), Application (Cardiopath, Heart First Aid, Other) Players and Region - Global Market Outlo...
$ 3500
Healthcare Distribution Comprehensive Study by Type (Pharmaceutical Product Distribution Services, Medical Device Distribution Services, Biopharmaceutical Product Distribution Services, Other Product...
$ 3650
Inhalable Drugs Comprehensive Study by Type (Dry Powder Formulation, Suspension Aerosol, Solution Aerosol), Application (Respiratory Disease, Non-respiratory Disease) Players and Region - Global Mark...
$ 3500
Chain Drugstores Comprehensive Study by Type (Regular Chain, Franchise Chain, Voluntary Chain), Application (B2B, B2C), Organization Size (Small & Medium Enterprises (SMEs), Large Enterprises), Distr...
$ 3350
Hypoxia Chamber Comprehensive Study by Type (84 X 35 Mm Plates, 27 X 60 Mm Plates, 12 X 100 Mm Plates, 12 X 96-Well Plates, 18 X 25 Cm2 Flasks), Application (Animal Research, Cell Research, Others) P...
$ 3500
Medical Cosmetology Product Comprehensive Study by Type (Hyaluronic Acid, Botulinum Toxin, Others), Application (Hospital, Clinic, Others) Players and Region - Global Market Outlook to 2030
$ 3500